

## Appendix 4E Financial Results and Corporate Update For the Year Ended 31 December 2025

### ASX Announcement

27 February 2026

#### Highlights:

- **Revenue Growth Despite Mixed Market Conditions:** Group revenue increased by 3% to \$5.8 million, supported by favourable foreign exchange movements and improved performance in the Dietary Supplements segment.
- **Margin Expansion:** Gross profit margin improved to 45% (FY2024: 42%), primarily due to strengthening of the Malaysian Ringgit in the second half of the year and disciplined cost management.
- **Statutory Result Impacted by One-Off Items:** The Group incurred \$1.09 million one-off legal settlement cost in relation to the ASIC matter and \$394,000 legal costs in relation to Prolimmune matter, partially offset by \$842,000 in debt recovery.
- **Malaysia operations:** \$152,000 operating profit before tax (excluding non-recurring debt recoveries)
- **Continued Cost Discipline:** Ongoing cost-reduction initiatives and internal efficiency improvements were implemented to support operational sustainability and financial discipline.

---

Holista Colltech Limited (ASX: HCT) (“**Holista**” or “the **Group**”) is providing the following commentary in respect to its unaudited results for the full year ended 31 December 2025 (“FY2025”).

All amounts are in Australian dollars and rounded to the nearest thousand unless otherwise stated.

**Revenue:** Overall Group revenue increased by 3% to approximately \$5.8 million, supported by favourable currency movements and improved contribution from the Dietary Supplements segment.

**Gross Profit:** Gross profit margin improved to 45% in FY2025 (FY2024: 42%). The improvement was primarily attributable to favourable foreign exchange movements, particularly the strengthening of the Malaysian Ringgit in the second half of the year, together with pricing discipline and cost management initiatives.

**Net Loss:** The Group recorded a net loss before tax of \$909,000 for FY2025.


On 11 December 2025, the Company received formal notice from ASIC of legal costs relating to the penalty, amounting to \$1.09 million, which has been recognised in the current year. The Company is currently in discussions with ASIC regarding the final terms of payment. In relation to the Prolmmune matter, the Company incurred legal costs of \$394,000 during FY2025, partially offset by debt recoveries totalling \$842,000.

### Malaysia Operation:

The Group's Malaysia operations, comprising the Dietary Supplements, Food Ingredients and Agriculture segments, recorded a profit before tax of \$889,000 in FY2025. This result included one-off debt recoveries recognised during the year.

Excluding the impact of these non-recurring recoveries, the Malaysia operations generated an operating profit before tax of \$152,000, following expense rationalisation and improved cost management across the segment.

**Cost Management and Operational Efficiency:** The Group continued to implement cost-cutting measures and initiatives aimed at improving internal efficiencies. These actions remain an ongoing focus to maintain financial discipline in a challenging operating environment.



*\*\*All figures are subject to annual audit.*

### Divisional Performance

Total revenue for FY2025 was approximately \$5.8 million, representing a 3% increase compared to FY2024. The increase was driven primarily by improved performance in Dietary Supplements and favourable foreign exchange movements, partially offset by lower Food Ingredients sales.

- **Dietary Supplements:** Revenue increased by 11.4% to \$5.22 million, reflecting favourable foreign exchange movements and selective pricing adjustments. Underlying customer demand remained broadly stable.
- **Food Ingredients:** Revenue declined by 49.7% to \$384,000, largely due to reduced customer demand and more cautious ordering patterns.
- **Ovine Collagen:** Revenue remained broadly unchanged at \$150,000, consistent with the prior year.
- **Infection Control / Agriculture segment:** Revenue of \$9,000 was recorded, reflecting the commencement of business activities during the year.

## Corporate Update

### Capital Management

During FY2025, the Group completed two capital raisings to support working capital requirements and strengthen the balance sheet:

- **Convertible Note (March 2025):** On 12 March 2025, the Company issued convertible notes totaling approximately \$1.53 million to provide essential working capital and financial flexibility during a critical operational transition.
- **Private Placement (October 2025):** On 30 October 2025, the Company completed a private placement, raising \$2.295 million through the issuance of 32,785,714 ordinary shares at \$0.07 per share. Conducted under ASX Listing Rule 7.1A, this placement significantly enhanced liquidity and long-term balance sheet strength.

### Leadership and Board Appointments

**Chief Executive Officer:** Mr. Leong Man Loong, also serving as Managing Director, was appointed Interim CEO on 3 January 2025 and formally confirmed as CEO on 3 July 2025, ensuring leadership stability during the Group's recovery phase. He has been an Executive Director since 3 January 2025.

**Chairperson:** Mr. Lai Kwok Kin was appointed Independent, Non-Executive Chair on 24 April 2025 to enhance governance and Board oversight. He first joined the board as an independent director on 19<sup>th</sup> March 2023.

**Non-Independent, Non-Executive Director:** Mr. Greg Pilant joined the Board as an Executive Director on 26 March 2025, bringing specialised expertise to the executive team.

**Independent, Non-Executive Directors:** Following the departures of Mr. David Deloub and Ms. Loren King, Mr. Robert Gemelli and Mr. Sam Yee Yuen Kong were appointed as independent directors on 14 May 2025.

### Legal Update – Prolmmune Matters

- **Prolmmune Action (CIV1440 of 2025):** The Supreme Court of Western Australia identified procedural deficiencies in Prolmmune's initial filing and issued remedial orders deeming the action to have been commenced by writ of summons. Prolmmune was required to file additional court documents to pursue recovery of a U.S. judgment amount.

Following these orders, Prolmmune filed an application for summary judgment, which Holista is actively contesting. After a postponement on 23 October 2025, the application was heard on 13 November 2025. The Company has presented its case and is now awaiting the Court's decision.

- **Holista Counter-Proceedings (CIV1332 of 2025):** On 31 March 2025, Holista initiated separate proceedings in the Supreme Court of Western Australia against Prolmmune and its director, Dr. Albert Crum. These proceedings involve allegations arising from facts and circumstances related to Prolmmune's action against Holista.
- **Legal Representation:** Holista has appointed new legal counsel to represent the Company in both matters.

- **Outlook:** The outcomes of both proceedings remain uncertain, including the possibility of consolidation. These matters may have material implications for the Company, particularly if summary judgment is granted in CIV1440 of 2025. Holista will provide further updates to the market as developments occur.

## Outlook

The Company anticipates the following, subject to funding, regulatory approvals and market conditions:

- Continued strength in the Malaysian Ringgit may support revenue translation into Australian dollars.
- The replacement Collie plant is expected to commence operations in 2H 2026, subject to funding and execution milestones.
- Maiden revenue contribution from sale of agricultural biotech and odour management solutions in 2026.

## Growth Initiatives

- **Direct-to-Consumer (B2C) Pivot:** With the appointment of a Digital Marketing Head in 4Q 2025, the dietary supplement division is accelerating its transition toward a direct-to-consumer model with stronger emphasis on social media marketing.
- **Innovation in Specialised Ingredients:** The Group has successfully developed sugar-free and low-sugar formulations in collaboration with existing customers and market leaders.
- **Next-Generation Nutrition:** Discussions are underway with strategic partners to commercialise new products in the post-biotics and low-glycemic-index (Low GI) sugar categories.
- **Agricultural Biotech:** A probiotic formulation for poultry has successfully completed trials, resulting in two initial orders totaling 3 metric tons worth approximately \$21,000 in 2H 2025. Delivery is scheduled for Q1 2026.
- **Odour Management Solutions:** Successful trials of nano-copper for effective odour neutralisation and prophylaxis have been completed with a customer. The Company expects to record initial orders by 1H 2026.

## Strategic Partnerships & Manufacturing

### Regenerex Pharma Agreement

On 25 August 2025 the Company entered into a binding agreement with U.S.-based Regenerex Pharma for the supply of proprietary, patented ovine and nano-collagen technologies and products.

- **Scope:** Regenerex holds exclusive global marketing rights for wound care applications and will fund all clinical trials and FDA regulatory approvals.
- **Revenue Commitments:** The agreement features scaling minimum purchase commitments, beginning at USD 50,000 in 2025.

- Leadership Synergy: Holista Non-Executive Director Mr. Greg Pilant also serves as Chairman and CEO of Regenerex Pharma, ensuring strong alignment between the two corporations.
- Market Impact: This partnership facilitates Holista's strategic entry into the high-value global medical and pharmaceutical markets.

### **Consolidated Australian Manufacturing**

In a strategic pivot to streamline operations, the Company has decided to consolidate its entire collagen manufacturing process in Collie, Western Australia.

- Rebuilding Collie Plant: The legacy collagen Collie plant was shut down Q4 2024 following cessation of the lease. Ground breaking for a replacement modular asset-light plant to be located at Collie Light Industrial Park is scheduled for 1H 2026. Collagen production is scheduled to commence in 2H 2026.
- Onshoring Nano-Technology: With the new plant in Collie, the Company intends to incorporate nano-element production on-site to deliver a "Fully Made-in-Australia" product line for both cosmetic and medical-grade nano-collagen.
- Infrastructure Update: Plans for the Sarawak nano-collagen facility have been discontinued in favour of this Australian expansion. We have commenced discussions with a potential Joint Venture partner for this new facility in Collie which will involve bringing in high-end nano-manufacturing capabilities to Western Australia.

This announcement has been approved by the Board of Directors.

**-ENDS-**

### **About Holista Colltech Limited**

Holista Colltech Limited (ASX: HCT) is a Perth-based innovator in health and wellness solutions. Operating across four dynamic business divisions—Dietary Supplements, Healthy Food Ingredients, Ovine Collagen, and Infection Control/Agriculture Solutions—Holista delivers cutting-edge products that blend nature and science for healthier lifestyles.

Our portfolio features leading nutritional supplements, patented low-GI food ingredients, premium disease-free ovine collagen, and eco-friendly, non-toxic sanitizers for everyday and industrial use. We are dedicated to sustainable, science-driven solutions that empower better living and create lasting value for our stakeholders worldwide.

### **For further information, please contact:**

Our Investor Mailing list: [investors@holistaco.com](mailto:investors@holistaco.com)

General Enquiries: [enquiries@holistaco.com](mailto:enquiries@holistaco.com)

#### **Australia**

283 Rokeby Road  
Subiaco WA 6008 Western Australia  
Australia  
P: +61 412 474 180

#### **Malaysia**

12th Floor, Amcorp Trade Centre, PJ Tower  
No. 18, Persiaran Barat off Jalan Timur  
46000, Petaling Jaya, Malaysia  
P: +603 7965 2828; F: +603 7965 2777

**Holista Colltech Limited**  
**Appendix 4E**  
**Preliminary final report**

**1. Company details**

Name of entity: Holista Colltech Limited  
ABN: 24094515992  
Reporting period: For the year ended 31 December 2025  
Previous period: For the year ended 31 December 2024

---

**2. Results for announcement to the market**

			\$
Revenues from ordinary activities	Up	2.96% to	5,764,055
Loss from ordinary activities after tax attributable to the owners of Holista Colltech Limited	Up	-1026.80% to	(948,921)
Loss for the year attributable to the owners of Holista Colltech Limited	Up	-1026.80% to	(948,921)

*Dividends*

There were no dividends paid, recommended or declared during the current financial period.

*Comments*

The loss for the consolidated entity after providing for income tax and non-controlling interest amounted to \$948,921 (31 December 2025: profit \$84,214).

---

**3. Net tangible assets**

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	<u>(0.12)</u>	<u>(1.18)</u>

---

**4. Control gained over entities**

Not applicable

---

**5. Loss of control over entities**

Not applicable.

---

**6. Dividends**

*Current period*

There were no dividends paid, recommended or declared during the current financial period.

*Previous period*

There were no dividends paid, recommended or declared during the previous financial period.

---

**7. Dividend reinvestment plans**

Not applicable.

---

**Holista Colltech Limited**  
**Appendix 4E**  
**Preliminary final report**

**8. Details of associates and joint venture entities**

Not applicable.

---

**9. Foreign entities**

*Details of origin of accounting standards used in compiling the report:*

Australian Accounting Standards

---

**10. Audit qualification or review**

*Details of audit/review dispute or qualification (if any):* Not Applicable

---

**11. Attachments**

Details of attachments (if any):

The Preliminary Final Report of Holista Colltech Limited for the year ended 31 December 2025 is attached.

---

**12. Signed**



Signed \_\_\_\_\_

Date: 27 February 2026

Jay Stephenson  
Company Secretary

**Holista Colltech Limited**  
**Appendix 4E**  
**Preliminary final report**

**Group Overview**

Holista Colltech Limited (ASX: HCT) (“**Holista**” or “the **Group**”) is providing the following commentary in respect to its unaudited results for the full year ended 31 December 2025 (“FY2025”).

All amounts are in Australian dollars and rounded to the nearest thousand unless otherwise stated.

**Revenue:** Overall Group revenue increased by 3% to approximately \$5.8 million, supported by favourable currency movements and improved contribution from the Dietary Supplements segment.

**Gross Profit:** Gross profit margin improved to 45% in FY2025 (FY2024: 42%). The improvement was primarily attributable to favourable foreign exchange movements, particularly the strengthening of the Malaysian Ringgit in the second half of the year, together with pricing discipline and cost management initiatives.

**Net Loss:** The Group recorded a net loss before tax of \$909,000 for FY2025.

On 11 December 2025, the Company received formal notice from ASIC of legal costs relating to the penalty, amounting to \$1.09 million, which has been recognised in the current year. The Company is currently in discussions with ASIC regarding the final terms of payment.

In relation to the Prolimmune matter, the Company incurred legal costs of \$394,000 during FY2025, partially offset by debt recoveries totalling \$842,000.

**Malaysia Operation:**

The Group’s Malaysia operations, comprising the Dietary Supplements, Food Ingredients and Agriculture segments, recorded a profit before tax of \$889,000 in FY2025. This result included one-off debt recoveries recognised during the year.

Excluding the impact of these non-recurring recoveries, the Malaysia operations generated an operating profit before tax of \$152,000, following expense rationalisation and improved cost management across the segment.

**Cost Management and Operational Efficiency:** The Group continued to implement cost-cutting measures and initiatives aimed at improving internal efficiencies. These actions remain an ongoing focus to maintain financial discipline in a challenging operating environment.

**Divisional Performance**

Total revenue for FY2025 was approximately \$5.8 million, representing a 3% increase compared to FY2024. The increase was driven primarily by improved performance in Dietary Supplements and favourable foreign exchange movements, partially offset by lower Food Ingredients sales.

- **Dietary Supplements:** Revenue increased by 11.4% to \$5.22 million, reflecting favourable foreign exchange movements and selective pricing adjustments. Underlying customer demand remained broadly stable.
- **Food Ingredients:** Revenue declined by 49.7% to \$384,000, largely due to reduced customer demand and more cautious ordering patterns.
- **Ovine Collagen:** Revenue remained broadly unchanged at \$150,000, consistent with the prior year.
- **Infection Control / Agriculture segment:** Revenue of \$9,000 was recorded, reflecting the commencement of business activities during the year.

**Outlook**

The Company anticipates the following, subject to funding, regulatory approvals and market conditions:

- Continued strength in the Malaysian Ringgit may support revenue translation into Australian dollars.
- The replacement Collie plant is expected to commence operations in 2H 2026, subject to funding and execution milestones; and
- Maiden revenue contribution from sale of agricultural biotech and odour management solutions in 2026.

## **Growth Initiatives**

- **Direct-to-Consumer (B2C) Pivot:** With the appointment of a Digital Marketing Head in 4Q 2025, the dietary supplement division is accelerating its transition toward a direct-to-consumer model with stronger emphasis on social media marketing.
- **Innovation in Specialised Ingredients:** The Group has successfully developed sugar-free and low-sugar formulations in collaboration with existing customers and market leaders.
- **Next-Generation Nutrition:** Discussions are underway with strategic partners to commercialise new products in the post-biotics and low-glycemic-index (Low GI) sugar categories.
- **Agricultural Biotech:** A probiotic formulation for poultry has successfully completed trials, resulting in two initial orders totaling 3 metric tons worth approximately \$21,000 in 2H 2025. Delivery is scheduled for Q1 2026.
- **Odour Management Solutions:** Successful trials of nano-copper for effective odour neutralisation and prophylaxis have been completed with a customer. The Company expects to record initial orders by 1H 2026.

## **Strategic Partnerships & Manufacturing**

### **Regenerex Pharma Agreement**

On 25 August 2025 the Company entered into a binding agreement with U.S.-based Regenerex Pharma for the supply of proprietary, patented ovine and nano-collagen technologies and products.

- **Scope:** Regenerex holds exclusive global marketing rights for wound care applications and will fund all clinical trials and FDA regulatory approvals.
- **Revenue Commitments:** The agreement features scaling minimum purchase commitments, beginning at USD 50,000 in 2025.
- **Leadership Synergy:** Holista Non-Executive Director Mr. Greg Pilant also serves as Chairman and CEO of Regenerex Pharma, ensuring strong alignment between the two corporations.
- **Market Impact:** This partnership facilitates Holista's strategic entry into the high-value global medical and pharmaceutical markets.

### **Consolidated Australian Manufacturing**

In a strategic pivot to streamline operations, the Company has decided to consolidate its entire collagen manufacturing process in Collie, Western Australia.

- **Rebuilding Collie Plant:** The legacy collagen Collie plant was shut down Q4 2024 following cessation of the lease. Ground breaking for a replacement modular asset-light plant to be located at Collie Light Industrial Park is scheduled for 1H 2026. Collagen production is scheduled to commence in 2H 2026.
- **Onshoring Nano-Technology:** With the new plant in Collie, the Company intends to incorporate nano-element production on-site to deliver a "Fully Made-in-Australia" product line for both cosmetic and medical-grade nano-collagen.
- **Infrastructure Update:** Plans for the Sarawak nano-collagen facility have been discontinued in favour of this Australian expansion. We have commenced discussions with a potential Joint Venture partner for this new facility in Collie which will involve bringing in high-end nano-manufacturing capabilities to Western Australia.

**Holista Colltech Limited**

**ABN 24094515992**

**Preliminary Final Report - 31 December 2025**

**Holista Colltech Limited**  
**Contents**  
**31 December 2025**

Consolidated statement of profit or loss and other comprehensive income	2
Consolidated statement of financial position	3
Consolidated statement of changes in equity	4
Consolidated statement of cash flows	5
Notes to the consolidated financial statements	6

**Holista Colltech Limited**  
**Consolidated statement of profit or loss and other comprehensive income**  
**For the year ended 31 December 2025**

	Note	Consolidated 2025 \$	2024 \$
<b>Revenue from contracts with customers</b>	1	5,764,055	5,598,239
Other income	2	26,756	65,410
<b>Expenses</b>			
Changes in inventories of finished goods and work in progress		289,739	66,423
Raw materials and consumables used		(3,071,464)	(2,849,290)
Distribution costs and other costs of sales		(372,124)	(441,292)
Advertising and promotion		(254,156)	(405,574)
Consultancy and professional fees		(1,607,922)	(98,432)
Depreciation and amortisation expense		(53,989)	(101,553)
Employee benefits		(1,785,964)	(2,152,019)
Finance costs		(107,428)	(119,448)
Foreign exchange		14,570	(165,168)
Impairment		829,569	1,286,394
Research and development		(36,066)	(72,064)
Other expenses	3	(544,123)	(509,574)
Share-Based Payment Expense		-	(33,479)
<b>Profit/(Loss) from continuing operations before income tax expense</b>		<b>(908,547)</b>	<b>(68,574)</b>
Income tax expense		(42,834)	(171,579)
<b>Loss after income tax expense for the year</b>		<b>(951,381)</b>	<b>(103,006)</b>
Profit / (Loss) from discontinued operations		-	15,855
<b>Net loss for the year</b>		<b>(951,381)</b>	<b>(87,151)</b>
<b>Other comprehensive income</b>			
<i>Items that will not be reclassified subsequently to profit or loss</i>			
Foreign currency translation		53,652	22,491
Other comprehensive profit/(Loss) for the year, net of tax		53,652	22,491
<b>Total comprehensive (loss) for the year</b>		<b>(897,729)</b>	<b>(64,660)</b>
(Loss) for the year is attributable to:			
Non-controlling interest		(2,460)	(2,937)
Owners of Holista Colltech Limited		(948,921)	(84,214)
		<b>(951,381)</b>	<b>(87,151)</b>
Total comprehensive income/(Loss) for the year is attributable to:			
Non-controlling interest		100,859	(224,236)
Owners of Holista Colltech Limited		(998,588)	159,576
		<b>(897,729)</b>	<b>(64,660)</b>
		<b>Cents</b>	<b>Cents</b>
Basic and Diluted (loss) per share from continuing operations		(0.26)	(0.04)
Basic and Diluted Profit/(loss) per share from discontinued operations		-	0.01

*The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes*

**Holista Colltech Limited**  
**Consolidated statement of financial position**  
**As at 31 December 2025**

	Note	Consolidated 2025 \$	Consolidated 2024 \$
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents	4	2,160,771	21,720
Trade and other receivables	5	950,606	1,031,049
Inventories	6	1,099,817	810,086
Income tax recoverable	8	89,586	112,974
Other current assets	9	811,267	583,684
<b>Total current assets</b>		<u>5,112,047</u>	<u>2,559,513</u>
<b>Non-current assets</b>			
Property, plant and equipment	10	741,038	746,263
Right-of-use assets	7	14,361	22,066
Intangible assets	11	5,989	14,052
<b>Total non-current assets</b>		<u>761,388</u>	<u>782,381</u>
<b>Total assets</b>		<u>5,873,435</u>	<u>3,341,894</u>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Trade and other payables	12	4,434,150	4,333,967
Contract liabilities	13	258,951	559,219
Borrowings	14	1,164,973	1,314,826
Leases	15	5,880	5,749
Short-term provisions		12,692	50,873
<b>Total current liabilities</b>		<u>5,876,646</u>	<u>6,264,634</u>
<b>Non-current liabilities</b>			
Borrowings	14	405,920	428,525
Leases	15	8,938	16,455
Long-term provisions		-	-
<b>Total non-current liabilities</b>		<u>414,858</u>	<u>444,980</u>
<b>Total liabilities</b>		<u>6,291,504</u>	<u>6,709,614</u>
<b>Net assets</b>		<u>(418,069)</u>	<u>(3,367,720)</u>
<b>Equity</b>			
Issued capital	16	25,717,958	21,870,577
Reserves	17	98,563	148,230
Accumulated losses		(24,697,133)	(23,748,211)
Equity attributable to the owners of Holista Colltech Limited		1,119,388	(1,729,404)
Non-controlling interest		(1,537,457)	(1,638,316)
<b>Total equity</b>		<u>(418,069)</u>	<u>(3,367,720)</u>

*The above consolidated statement of financial position should be read in conjunction with the accompanying notes*

**Holista Colltech Limited**  
**Consolidated statement of changes in equity**  
**For the year ended 31 December 2025**

<b>Consolidated</b>	<b>Issued capital \$</b>	<b>Foreign Currency Translation Reserve \$</b>	<b>Accumulated Losses \$</b>	<b>Non- controlling interest \$</b>	<b>Total equity \$</b>
Balance at 1 January 2024	21,787,478	(95,559)	(23,663,997)	(1,414,081)	(3,386,159)
Loss after income tax expense for the year	-	-	(84,214)	(2,937)	(87,151)
Other comprehensive income/ (Loss) for the year, net of tax	-	243,789	-	(221,298)	22,491
Total comprehensive income/ (Loss) for the year	-	243,789	(84,214)	(224,235)	(64,660)
Shares issued during the year	83,099	-	-	-	83,099
Balance at 31 December 2024	<u>21,870,577</u>	<u>148,230</u>	<u>(23,748,211)</u>	<u>(1,638,316)</u>	<u>(3,367,720)</u>

<b>Consolidated</b>	<b>Issued capital \$</b>	<b>Foreign Currency Translation Reserve \$</b>	<b>Accumulated Losses \$</b>	<b>Non- controlling interest \$</b>	<b>Total equity \$</b>
Balance at 1 January 2025	21,870,577	148,230	(23,748,211)	(1,638,316)	(3,367,720)
Loss after income tax expense for the year	-	-	(948,922)	(2,460)	(951,382)
Other comprehensive income /(Loss) for the year, net of tax	-	(49,667)	-	103,319	53,652
Total comprehensive income/(Loss) for the year	-	(49,667)	(948,922)	100,859	(897,730)
Shares issued during the year	3,847,381	-	-	-	3,847,381
Balance at 31 December 2025	<u>25,717,958</u>	<u>98,563</u>	<u>(24,697,133)</u>	<u>(1,537,457)</u>	<u>(418,069)</u>

*The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes*

**Holista Colltech Limited**  
**Consolidated statement of cash flows**  
**For the year ended 31 December 2025**

	Note	2025 \$	Consolidated 2024 \$
<b>Cash flows from operating activities</b>			
Receipts from customers		7,261,931	6,625,839
Payments to suppliers and employees		(7,588,510)	(6,445,800)
Finance costs		(107,428)	(119,448)
Interest received		4,874	3,687
Income tax paid		(17,308)	(192,818)
Tax incentive benefit		-	14,795
ASIC penalty		(900,000)	(900,000)
		<u>(1,346,441)</u>	<u>(1,013,745)</u>
<b>Cash flows from investing activities</b>			
Purchase of property, plant and equipment		(23,353)	(7,040)
Proceeds from disposal of property, plant and equipment		(153,006)	561,805
Increase of deposits		-	137,353
		<u>(176,359)</u>	<u>692,118</u>
<b>Cash flows from financing activities</b>			
Proceeds from issue of shares	16	3,847,381	-
Proceeds from borrowings, net		6,195,937	6,609,362
Repayment of borrowings		(6,387,767)	(6,231,815)
Repayment of lease liabilities		(7,765)	(207,379)
Repayment of Term Loans		-	(26,414)
		<u>3,647,786</u>	<u>143,754</u>
<b>Net cash from generated from financing activities</b>			
		<u>3,647,786</u>	<u>143,754</u>
Net increase / (decrease) in cash and cash equivalents		2,124,986	(177,873)
Cash and cash equivalents at the beginning of the financial year		21,720	59,767
Change in foreign currency held		14,064	139,826
		<u>14,064</u>	<u>139,826</u>
Cash and cash equivalents at the end of the financial year	4	<u><u>2,160,770</u></u>	<u><u>21,720</u></u>

*The above consolidated statement of cash flows should be read in conjunction with the accompanying notes*

**Holista Colltech Limited**  
**Notes to the consolidated financial statements**  
**31 December 2025**

**Note 1. Revenue from contracts with customers**

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
Revenue from contracts with customers	5,764,055	5,598,239

**Note 2. Other income**

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
Gain on disposal of property, plant and equipment	150	45,407
Tax incentive benefit	-	14,795
Interest income	4,874	5,208
Rental Income	21,732	-
Other income	26,756	65,410

**Note 3. Expenses**

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
<b>Loss before income tax includes the following specific expenses:</b>		
Impairment		
Reversal of Impairment of other assets	-	(92,768)
(Recovery)/Impairment of Related Party Loans	-	(561,805)
Reversal of Impairment of Credit Losses	(829,569)	(631,821)
Total Impairment	(829,569)	(1,286,394)
 <i>Other Expenses</i>		
Compliance and regulatory costs	167,836	107,984
Insurance	19,694	54,528
Other expenses	14,974	5,931
Stock written off	24,333	14,376
Collie factory maintenance costs	3,707	48,802
Audit fees	156,787	119,045
Office expense and other occupancy costs	156,792	158,908
Total Other Expenses	544,123	509,574
 <i>Employee Benefit Expense Short-term</i>		
Salary and wages, including directors fees	1,234,827	1,551,480
Superannuation	170,008	210,004
Medical and Insurance	69,109	73,709
Bonus and Incentive	122,441	112,293
Travel	135,160	143,502
Others	54,419	61,031
Total Employee Benefit Expense Short-term	1,785,964	2,152,019

**Holista Colltech Limited**  
**Notes to the consolidated financial statements**  
**31 December 2025**

**Note 4. Cash and cash equivalents**

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
<i>Current assets</i>		
Cash at bank	1,056,771	21,720
Term deposits at call	1,104,000	-
	<u>2,160,771</u>	<u>21,720</u>

**Note 5. Trade and other receivables**

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
<i>Current assets</i>		
Trade receivables	1,146,681	2,616,214
Less: Allowance for expected credit losses	<u>(313,646)</u>	<u>(1,713,824)</u>
	833,035	902,390
Other receivables	58,739	65,323
Amounts advanced to a third party	475,157	475,157
Less : Allowance for expected credit losses	<u>(475,157)</u>	<u>(475,157)</u>
Interest receivable	58,832	63,336
	<u>950,606</u>	<u>1,031,049</u>

**Note 6. Inventories**

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
<i>Current assets</i>		
Raw materials - at cost	655,464	446,959
Finished goods - at cost	308,846	367,645
Less: Finished goods stock written off	<u>(24,333)</u>	<u>(71,720)</u>
Stock-in-transit	159,840	67,202
	<u>1,099,817</u>	<u>810,086</u>

**Holista Colltech Limited**  
**Notes to the consolidated financial statements**  
**31 December 2025**

**Note 7. Right-of-use assets**

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
<i>Non-current assets</i>		
Properties	14,361	22,066
Motor vehicles	-	-
	<u>14,361</u>	<u>22,066</u>

*Reconciliations*

Reconciliations of the written down values at the beginning and end of the current financial year are set out below:

<b>Consolidated</b>	Properties \$	Motor vehicles \$	Total \$
Balance at 1 January 2025	22,066	-	22,066
Additions	-	-	-
Disposals	-	-	-
Exchange differences	501	-	501
Depreciation expense	<u>(8,206)</u>	<u>-</u>	<u>(8,206)</u>
Balance at 31 December 2025	<u>14,361</u>	<u>-</u>	<u>14,361</u>

**Note 8. Income tax recoverable**

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
<i>Current assets</i>		
Income tax refund due	<u>89,586</u>	<u>112,974</u>

**Note 9. Other current assets**

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
<i>Current assets</i>		
Prepayments	95,171	102,283
Security deposits	355,366	195,441
Other deposits	21,293	24,163
Right-of-return assets	<u>339,437</u>	<u>261,797</u>
	<u>811,267</u>	<u>583,684</u>

**Holista Colltech Limited**  
**Notes to the consolidated financial statements**  
**31 December 2025**

**Note 10. Property, plant and equipment**

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
<i>Non-current assets</i>		
Freehold land and buildings	1,168,404	1,056,810
Less: Accumulated depreciation and impairment	<u>(467,794)</u>	<u>(359,315)</u>
	700,610	697,495
Plant and equipment	2,089,280	2,149,297
Less: Accumulated depreciation	<u>(2,048,852)</u>	<u>(2,100,529)</u>
	40,428	48,768
Total property, plant and equipment	<u><u>741,038</u></u>	<u><u>746,263</u></u>

*Reconciliations*

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

<b>Consolidated</b>	Freehold land and buildings \$	Plant and equipment \$	Total \$
Balance at 1 January 2024	635,618	81,354	716,972
Additions	-	2,589	2,589
Exchange rate differences	83,011	4,170	87,181
Depreciation expense	<u>(21,134)</u>	<u>(39,345)</u>	<u>(60,479)</u>
Balance at 31 December 2024	697,495	48,768	746,263
Additions	10,868	12,616	23,485
Exchange rate differences	16,086	(568)	15,518
Depreciation expense	<u>(23,839)</u>	<u>(20,388)</u>	<u>(44,227)</u>
Balance at 31 December 2025	<u><u>700,610</u></u>	<u><u>40,428</u></u>	<u><u>741,038</u></u>

**Note 11. Intangible assets**

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
<i>Non-current assets</i>		
Goodwill	<u>-</u>	<u>-</u>
Patents and licences	112,093	116,370
Less: Accumulated amortisation	<u>(106,104)</u>	<u>(102,318)</u>
	5,989	14,052
	<u><u>5,989</u></u>	<u><u>14,052</u></u>

**Holista Colltech Limited**  
**Notes to the consolidated financial statements**  
**31 December 2025**

**Note 11. Intangible assets (continued)**

*Reconciliations*

Reconciliations of the written down values at the beginning and end of the current and previous financial years are set out below:

<b>Consolidated</b>	Patents and Licences \$	Total \$
Balance at 31 December 2024	7,443	7,443
Additions	4,451	4,451
Exchange differences	19,421	19,421
Transfers (out)	(14,841)	(14,841)
Amortisation expense	(2,422)	(2,422)
	<hr/>	<hr/>
Balance at 31 December 2025	14,052	14,052
Additions	-	-
Write off	(6,105)	(6,105)
Exchange differences	319	319
Transfers (out)	-	-
Amortisation expense	(2,277)	(2,277)
	<hr/>	<hr/>
Balance at 31 December 2025	5,989	5,989

**Note 12. Trade and other payables**

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	\$	\$
<i>Current liabilities</i>		
Trade payables	1,867,164	2,080,804
Accruals	1,478,126	495,621
Dividends payable	25,730	27,700
Refund liability	934,345	708,354
Amount due to director	15,536	-
Other payables	113,249	1,021,488
	<hr/>	<hr/>
	4,434,150	4,333,967
	<hr/> <hr/>	<hr/> <hr/>

**Note 13. Contract liabilities**

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	\$	\$
<i>Current liabilities</i>		
Advance deposits and deferred revenue	258,951	559,219
	<hr/> <hr/>	<hr/> <hr/>

**Holista Colltech Limited**  
**Notes to the consolidated financial statements**  
**31 December 2025**

**Note 14. Borrowings**

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
<i>Current liabilities</i>		
Term loan	39,349	38,475
Banker's acceptance	1,110,048	1,259,582
Loan from a third parties	15,576	16,769
	<u>1,164,973</u>	<u>1,314,826</u>
<i>Non-current liabilities</i>		
Term loan	405,920	428,525
	<u>1,570,893</u>	<u>1,743,351</u>

**Note 15. Leases**

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
<i>Current liabilities</i>		
Current	5,880	5,749
<i>Non-current liabilities</i>		
Non-current	8,938	16,455
	<u>14,818</u>	<u>22,204</u>

**Note 16. Issued capital**

	<b>Consolidated</b>			
	<b>2025</b>	<b>2024</b>	<b>2025</b>	<b>2024</b>
	<b>Shares</b>	<b>Shares</b>	<b>\$</b>	<b>\$</b>
Ordinary shares - fully paid	<u>367,834,364</u>	<u>285,766,714</u>	<u>25,717,958</u>	<u>21,870,577</u>

**Note 17. Reserves**

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
Foreign currency reserve	98,563	148,230
	<u>98,563</u>	<u>148,230</u>

**Note 18. Dividends**

There were no dividends paid, recommended or declared during the current or previous financial year.